New Launch17 Nov 2025, 11:23 am
Marksans Pharma's Subsidiary Gets Marketing Authorisation from UK MHRA
AI Summary
Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has announced that its wholly owned subsidiary, Relonchem Limited in the UK, has received Marketing Authorisation for its products from the UK MHRA. The products include Mefenamic Acid 250 mg Film-Coated Tablets and Mefenamic Acid 500 mg Film-Coated Tablets.
Key Highlights
- Marksans Pharma's subsidiary, Relonchem Limited, receives Marketing Authorisation from UK MHRA
- The authorised products include Mefenamic Acid 250 mg and 500 mg Film-Coated Tablets
- This development marks a significant milestone for Marksans Pharma in the UK market